SXTPNasdaq

60 DEGREES PHARMACEUTICALS, INC.

Healthcare·Immunology·Commercial·Washington, DC, United States
ImmunologyInfectious Disease

60 DEGREES PHARMACEUTICALS, INC. (SXTP): 3 pipeline candidates · 1 upcoming catalyst · ~5 mo cash runway · 4 clinical trials. Updated within the last hour.

5.7/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway1.3

4.6 months

Financial Health9.4

D/E 0.42 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst Momentum2.0

1 upcoming, next in ~3454d

Insider SignalN/A

N/A

A transparent, data-derived signal for 60 DEGREES PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$4.5M

Cash

$3.3M

Quarterly Burn

$2.7M

Runway

4.6 mo

Revenue

$162K

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~Nov 2026
Today~125 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (3 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

6

Total value held

$285K

HolderSharesValue
kathmere capital management, llc144,683$253K
geode capital management, llc16,295$29K
barclays plc1,856$3K
osaic holdings, inc.25$43
twin peaks wealth advisors, llc8$14
citigroup inc1$2
4 clinical trials·CEO: Dr. Geoffrey Stuart Dow Ph.D.

Frequently asked questions

How many drug candidates are in 60 DEGREES PHARMACEUTICALS, INC.'s pipeline?

60 DEGREES PHARMACEUTICALS, INC. (SXTP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is 60 DEGREES PHARMACEUTICALS, INC.'s lead drug candidate?

60 DEGREES PHARMACEUTICALS, INC.'s most advanced tracked candidate is arakoda (Approved) for Malaria prevention.

What is 60 DEGREES PHARMACEUTICALS, INC.'s next catalyst?

60 DEGREES PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ARAKODA" — expected December 2, 2035.

What is 60 DEGREES PHARMACEUTICALS, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, 60 DEGREES PHARMACEUTICALS, INC. has approximately 4.6 months of cash runway.

What is 60 DEGREES PHARMACEUTICALS, INC.'s market capitalization?

60 DEGREES PHARMACEUTICALS, INC.'s market capitalization is approximately $4.5M.

Get the full picture on 60 DEGREES PHARMACEUTICALS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.